🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07767175
Recruiting Phase 1

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

NCT07767175 · tracked via the Priya Life Science USA tracker
Sponsor
Novo Nordisk A/S
Phase
Phase 1
Started
2026-08-12
Last updated
2026-09-04

Condition(s) studied

OverweightObesity

Investigational drug(s) / intervention(s)

NNC0721-8060SemaglutidePlacebo

NNC0721-8060: NNC0721-8060 will be administered subcutaneously.

Semaglutide: Semaglutide will be administered subcutaneously.

Placebo: Placebo will be administered subcutaneously.

Study summary

The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female (sex at birth). * Age 18-55 years (both inclusive) at the time of signing informed consent. * Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator. * Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Previous randomisation in this study. * History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions. * Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception. * Current participation (signed informed consent) in any other interventional clinical study. * Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening. * Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol. * Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \[mmol/mol\]) at screening.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
ICON Early Phase Services, LLC Lenexa Kansas Recruiting
ICON San Antonio Texas Not Yet Recruiting

On this site

📄 Ozempic (semaglutide) drug profile →

More Novo Nordisk A/S trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07767175 on ClinicalTrials.gov ↗ ← All trials in the USA